EUCTR2006-003034-15-IT进行中（未招募）1 期
Trattamento dell’epatocarcinoma (HCC) mediante chemioembolizzazione (TACE) selettiva tradizionale versus TACE selettiva con microsfere caricate con Doxorubicina: studio monocentrico, randomizzato, in aperto, controllato. - RAD01
AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI0 个研究点目标入组 214 人开始时间: 2007年7月6日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 214
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •The English version will follow
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •The English version will follow
研究者
相似试验
进行中（未招募）
不适用
Treatment of advanced hepatocellular carcinoma (HCC) with portal vein thrombosis by hepatic intra-arterial injection of microspheres loaded with Yttrium-90 (Thera-Sphere) - RAD-09advanced hepatocellular carcinoma (HCC) with portal vein thrombosisMedDRA version: 9.1Level: LLTClassification code 10024662MedDRA version: 9.1Level: PTClassification code 10019713EUCTR2009-016475-29-ITAZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
招募中
不适用
Sequential therapy for hepatocellular carcinoma -Real world evidence of TKI in prospective observational studyhepatocellular carcinomaJPRN-UMIN000038867Kyushu Study group of Clinical Cancer500
已完成
不适用
Multimodal treatment of HCC, Bile duct cancer and metastatic liver cancer: a multi-institutional retrospective studyHepatocellular carcinoma, intrahepatic cholangiocarcinoma, neuroendocrine or colorectal liver metastasesJPRN-UMIN000033823Yokohama City University Hospital, Department of Gastoenterological Surgery1,829
进行中（未招募）
1 期
Evaluation of the efficacy and tolerance of a chemotherapy by Idarubicin and Lipiodol emulsion administer in the liver, by the hepatic artery, on hepatocellular carcinoma.The research hypothesis is that hepatic locoregional treatment without embolization, using a more cytotoxic anticancer molecule (Idarubicin) than those conventionally used, would be more effective.MedDRA version: 20.0Level: LLTClassification code 10019828Term: Hepatocellular carcinoma non-resectableSystem Organ Class: 100000004864EUCTR2017-004859-22-FRniversity Hospital of Monptellier53
招募中
2 期
Neoadjuvant HAIC and PD-1 Plus Adjuvant PD-1 for High-risk Recurrent HCCBeyond Milan CriteriaHepatocellular CarcinomaNCT06467799Sun Yat-sen University39